Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 10857 · Faster Clinical Trials Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 355c Research into pediatric uses for drugs and biological products

+10 −5Shown
More for 21 U.S.C. § 355c
Read § 355cOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 505B(l) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(l)) is amended to read as follows:(l) Biosimilar biological products.— A biological product for which an application is submitted under section 351(k) of the Public Health Service Act shall be considered to have a new active ingredient for purposes of this section only if— (1) the application seeks licensure for …

§ 355c(k)–(m)

Start of § 355c to (k) unchanged ·

(1) In general; exemption for orphan indications Unless the Secretary requires otherwise by regulation and except as provided in paragraph (2), this section does not apply to any drug or biological product for an indication for which orphan designation has been granted under section 360bb of this title.

(2) Applicability despite orphan designation of certain indications This section shall apply with respect to a drug or biological product for which an indication has been granted orphan designation under 360bb3 of this title if the investigation described in subsection (a)(3) applies to the drug or biological product as described in subsection (a)(1)(B).

(l) [struck: New][inserted: Biosimilar] [struck: active][inserted: biological] [struck: ingredient][inserted: products.—] [inserted: A biological product for which an application is submitted under section 351(k) of the Public Health Service Act shall be considered to have a new active ingredient for purposes of this section only if—]

(1) [struck: Non-interchangeable biosimilar biological product] [inserted: the application seeks licensure for a claimed indication—]

(A) [inserted: that has been approved for a relevant pediatric population; or]

(B) [inserted: for which there is a deferral of a relevant pediatric assessment under subsection (a)(4) of this section for the reference product applicant; and]

[struck: A biological product that is biosimilar to a reference product under section 262 of title 42, and that the Secretary has not determined to meet the standards described in subsection (k)(4) of such section for interchangeability with the reference product, shall be considered to have a new active ingredient under this section.]

(2) [struck: Interchangeable biosimilar biological product] [struck: A][inserted: a] [struck: biological][inserted: pediatric] [struck: product][inserted: assessment] [struck: that][inserted: under] [struck: is][inserted: this] [struck: interchangeable][inserted: section] [struck: with][inserted: would] [inserted: not involve the development of ]a [struck: reference][inserted: biological] product [struck: under][inserted: with] [struck: section][inserted: a] [struck: 262][inserted: strength,] [struck: of][inserted: dosage] [struck: title][inserted: form,] [struck: 42][inserted: route] [struck: shall][inserted: of] [struck: not][inserted: administration,] [struck: be][inserted: and] [struck: considered][inserted: condition] [struck: to][inserted: of] [struck: have][inserted: use] [struck: a][inserted: for] [struck: new][inserted: which] [struck: active][inserted: there] [struck: ingredient][inserted: would] [struck: under][inserted: not] [struck: this][inserted: be] [struck: section][inserted: a reference product].

(m) List of primary molecular targets

(1) In general Within one year of August 18, 2017, the Secretary shall establish and update regularly, and shall publish on the internet website of the Food and Drug Administration—

Rest of § 355c unchanged ·

21 U.S.C. § 374 Inspection

+13 −0Shown
More for 21 U.S.C. § 374
Read § 374Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 704 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 374) is amended by adding at the end the following:(i) (1) With respect to an owner, operator, or agent in charge of an establishment carrying out a clinical investigation intended to support an application under section 505 of this Act or section 351 of the Public Health Service Act (42 U.S.C. 262), the Secretary shall, as part …

§ 374(h)–(i)

Start of § 374 to (h)(2)(B)(i) unchanged ·

(ii) with respect to actions proposed to be taken by a device establishment in a response to a report received by such establishment pursuant to subsection (b) that involve a public health priority, that implicate systemic or major actions, or relate to emerging safety issues (as determined by the Secretary).

(3) Nothing in this subsection affects the authority of the Secretary to conduct inspections otherwise permitted under this chapter in order to ensure compliance with this chapter.

(i)

(1) [inserted: With respect to an owner, operator, or agent in charge of an establishment carrying out a clinical investigation intended to support an application under section 505 of this Act or section 351 of the Public Health Service Act (42 U.S.C. 262), the Secretary shall, as part of the inspection of such establishment under this section—]

(A) [inserted: require such owner, operator, or agent to pre-certify that such clinical investigation complies with the standard, entitled “Good Clinical Practice”, maintained by the International Council for Harmonisation; and]

(B) [inserted: verify, on-site or remotely, that, prior to the acceptance of data from any clinical trial site, contract research organization, or data management vendor that meets the criteria of a biotechnology company of concern (as defined in section 851(f)(2) of the National Defense Authorization Act for Fiscal Year 2026 (Public Law 119–60)), such clinical investigation complies with—]

(i) [inserted: such standard; and]

(ii) [inserted: data security protocols.]

(2) [inserted: The Secretary may require an owner, operator, or agent described in paragraph (1) to pay a fee to cover any cost related to the activities described in such paragraph.]

21 U.S.C. § 383 Office of International Relations

+18 −3Shown
More for 21 U.S.C. § 383
Read § 383Only this section
5 changes the bill asks for here, 5 carried out
  1. Carried out:

    in paragraph (1), by striking , and and inserting a semicolon;

  2. Carried out:

    by redesignating paragraph (2) as paragraph (4); and

  3. Carried out:

    by adding after paragraph (1) the following:(2) the standard, entitled “Good Clinical Practice”, maintained by the International Council for Harmonisation;; and

  4. Carried out:

    by adding at the end the following:(d) (1) The Secretary shall expand and coordinate efforts, including through enhanced international collaboration, to ensure compliance with the standard, entitled “Good Clinical Practice”, maintained by the International Council for Harmonisation for clinical trials conducted …

  5. Carried out:

    Section 803(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 383(b)) is amended by inserting after paragraph (2), as inserted by section 203(a)(1)(C), the following:(3) the bioresearch monitoring program implemented by the Food and Drug Administration through compliance programs shall identify ways to— (A) allow such countries to rely on any inspection conducted by the Food and Drug Administration related to an establishment performing …

§ 383(a)–(c)

§ 383. Office of International Relations

(a) Establishment There is established in the Department of Health and Human Services an Office of International Relations.

(b) Agreements with foreign countries In carrying out the functions of the office under subsection (a), the Secretary may enter into agreements with foreign countries to facilitate commerce in devices between the United States and such countries consistent with the requirements of this chapter. In such agreements, the Secretary shall encourage the mutual recognition of—

(1) good manufacturing practice regulations promulgated under section 360j(f) of this title[struck: , and][inserted: ;]

(2) [inserted: the standard, entitled “Good Clinical Practice”, maintained by the International Council for Harmonisation;]

(3) [inserted: the bioresearch monitoring program implemented by the Food and Drug Administration through compliance programs shall identify ways to—]

(A) [inserted: allow such countries to rely on any inspection conducted by the Food and Drug Administration related to an establishment performing clinical research;]

(B) [inserted: reduce the regulatory burden on such an establishment in the United States; and]

(C) [inserted: provide the Secretary with maximum flexibility to focus resources related to inspections and compliance on establishments that pose the greatest risk to data integrity or safety.]

[struck: (2)] [inserted: (4)] other regulations and testing protocols as the Secretary determines to be appropriate.

(c) Harmonizing regulatory requirements

(1) The Secretary shall support the Office of the United States Trade Representative, in consultation with the Secretary of Commerce, in meetings with representatives of other countries to discuss methods and approaches to reduce the burden of regulation and harmonize regulatory requirements if the Secretary determines that such harmonization continues consumer protections consistent with the purposes of this chapter.

§ 383(c)–(d)

(c)(2)–(3) unchanged ·

(4) With respect to devices, the Secretary may, when appropriate, enter into arrangements with nations regarding methods and approaches to harmonizing regulatory requirements for activities, including inspections and common international labeling symbols.

(5) Paragraphs (1) through (4) shall not apply with respect to products defined in section 321(ff) of this title.

(d)

(1) [inserted: The Secretary shall expand and coordinate efforts, including through enhanced international collaboration, to ensure compliance with the standard, entitled “Good Clinical Practice”, maintained by the International Council for Harmonisation for clinical trials conducted outside the United States.]

(2) [inserted: The Secretary shall, in consultation with relevant nations and the International Council for Harmonisation, foster global regulatory alignment to modernize clinical early-stage medical product development, integrate real-world data and digital health information into clinical investigations, and ensure regulatory acceptance of investigations conducted by clinical trial networks embedded in routine practice.]

21 U.S.C. § 384e Recognition of foreign government inspections

+20 −7Shown
More for 21 U.S.C. § 384e
Read § 384eOnly this section
7 changes the bill asks for here, 7 carried out
  1. Carried out:

    in paragraph (2), by striking and at the end;

  2. Carried out:

    in paragraph (3), by striking the period at the end and inserting ; and; and

  3. Carried out:

    by inserting after paragraph (3) the following:(4) shall implement a procedure for exchanging inspection reports with a foreign government or an agency of a foreign government that the Secretary has entered into an arrangement or agreement with under this section to avoid duplicating an inspection in which a foreign …

  4. Carried out:

    by redesignating subsection (c) as subsection (d);

  5. Carried out:

    by inserting after subsection (b) the following:(c) Risk-Based prioritization plan.— For purposes of increasing the rate of inspections, the Secretary shall implement a plan for the use of risk-based prioritization for inspections of establishments registered under section 510, which shall include consideration of— (1) the …

  6. Carried out:

    by striking Beginning not later and inserting the following:(A) In general.— Beginning not later; and

  7. Carried out:

    by adding at the end the following:(B) Reporting on mutual recognition.— The report under subparagraph (A) shall include, with respect to the period covered by the report an update on the status of any agreement the Secretary enters into with a foreign country under section 803 related to encouraging the mutual …

§ 384e(a)–(c)

§ 384e. Recognition of foreign government inspections

(a) Inspection The Secretary—

(1) may enter into arrangements and agreements with a foreign government or an agency of a foreign government to recognize the inspection of foreign establishments registered under section 360(i) of this title in order to facilitate preapproval or risk-based inspections in accordance with the schedule established in paragraph (2) or (3) of section 360(h) of this title;

(2) may enter into arrangements and agreements with a foreign government or an agency of a foreign government under this section only with a foreign government or an agency of a foreign government that the Secretary has determined as having the capability of conducting inspections that meet the applicable requirements of this chapter;[struck: and]

(3) shall perform such reviews and audits of drug safety programs, systems, and standards of a foreign government or agency for the foreign government as the Secretary deems necessary to determine that the foreign government or agency of the foreign government is capable of conducting inspections that meet the applicable requirements of this chapter[struck: .][inserted: ; and]

(4) [inserted: shall implement a procedure for exchanging inspection reports with a foreign government or an agency of a foreign government that the Secretary has entered into an arrangement or agreement with under this section to avoid duplicating an inspection in which a foreign establishment registered under section 510 was found to be in compliance with good manufacturing practice regulations promulgated under section 501.]

(b) Results of inspection The results of inspections performed by a foreign government or an agency of a foreign government under this section may be used as—

(2) for any other purposes as determined appropriate by the Secretary.

(c) [inserted: Risk-Based prioritization plan.—] [inserted: For purposes of increasing the rate of inspections, the Secretary shall implement a plan for the use of risk-based prioritization for inspections of establishments registered under section 510, which shall include consideration of—]

(1) [inserted: the history of such an establishment with respect to complying with good manufacturing practice regulations promulgated under section 520(f);]

(2) [inserted: the inherent risk of the drug or device manufactured, prepared, propagated, compounded, or processed (as defined in section 510) at such establishment; and]

(3) [inserted: the availability of recent inspection reports from a foreign government or an agency of a foreign government that the Secretary has entered into an arrangement or agreement with under this section.]

[struck: (c)] [inserted: (d)] Periodic review

(1) In general Beginning not later than 1 year after December 29, 2022, the Secretary shall periodically assess whether additional arrangements and agreements with a foreign government or an agency of a foreign government, as allowed under this section, are appropriate.

(2) Reports to Congress

(A) [inserted: In general.—] [inserted: Beginning not later than 4 years after December 29, 2022, and every 4 years thereafter, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report describing the findings and conclusions of each review conducted under paragraph (1).]

(B) [inserted: Reporting on mutual recognition.—] [inserted: The report under subparagraph (A) shall include, with respect to the period covered by the report an update on the status of any agreement the Secretary enters into with a foreign country under section 803 related to encouraging the mutual recognition of good manufacturing practice regulations promulgated under section 520(f) with respect to inspections.]

[struck: Beginning not later than 4 years after December 29, 2022, and every 4 years thereafter, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report describing the findings and conclusions of each review conducted under paragraph (1).]

42 U.S.C. § 262 Regulation of biological products

+76 −5112 of 17 shown
More for 42 U.S.C. § 262
Read § 262Only this section
17 changes the bill asks for here, 12 carried out
  1. Carried out:

    in the subsection heading, by striking or interchangeable;

  2. Carried out:

    by striking subparagraph (B);

  3. Not carried out:

    by redesignating clauses (ii) and (iii) of subparagraph (A) as subparagraphs (B) and (C), respectively, and adjusting the margins accordingly;

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: redesignating clauses (X) and (X) of subparagraph (X) as subparagraphs (X) and (X), respectively, and adjusting the margins accordingly;
  4. Carried out:

    in clause (i), by redesignating subclauses (I) through (V) as clauses (i) through (v), respectively, and adjusting the margins accordingly;

  5. Carried out:

    in clause (i), as so redesignated by clause (i) of this subparagraph, by redesignating items (aa) through (cc) as subclauses (I) through (III), respectively, and adjusting the margins accordingly;

  6. Carried out:

    in subclause (II) of clause (i), as so redesignated by clause (ii) of this subparagraph, by striking item (aa) or (cc) and inserting subclause (I) or (III); and

  7. Not carried out:

    by striking (A) In General and all that follows through An application submitted under this subsection shall include information and inserting the following:(A) In general.— An application submitted under this subsection shall include information;

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and all that follows through QTEXT and inserting the following: QCONTENT;
  8. Not carried out:

    in subparagraph (B), as so redesignated by subparagraph (B) of this paragraph, by striking clause (i)(I) and inserting subparagraph (A)(i); and

    The bill points to subparagraph (B) of § 262(k)(2), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no subparagraph (B) in /us/usc/t42/s262/k/2
  9. Not carried out:

    in subparagraph (C), as so redesignated by subparagraph (B) of this paragraph, by redesignating subclauses (I) through (III) as clauses (i) through (iii), respectively, and adjusting the margins accordingly;

    The bill points to subparagraph (C) of § 262(k)(2), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no subparagraph (C) in /us/usc/t42/s262/k/2
  10. Not carried out:

    by amending subparagraph (A) of paragraph (3) to read as follows:(A) the Secretary determines that the information submitted in the application (or the supplement) is sufficient to show that the biological product is biosimilar to the reference product; and;

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: amending subparagraph (X) of paragraph (X) to read as follows: QCONTENT;
  11. Carried out:

    by amending paragraph (4) to read as follows:(4) Interchangeability.— (A) In general.— A biological product licensed under this subsection shall be deemed to be interchangeable with the reference product, subject to subparagraph (B). (B) Timing of deemed interchangeability.— (i) Licensure on or after transition date.— A …

  12. Carried out:

    by amending paragraph (6) to read as follows:(6) Transition with respect to preserving first interchangeable exclusivity with respect to certain biological products.— With respect to a biological product licensed under this subsection before the date of enactment of the Faster Clinical Trials Act, for which there was an …

  13. Carried out:

    in clause (i), by striking class; and and inserting class.;

  14. Carried out:

    by striking clause (ii); and

  15. Carried out:

    by striking description of— and all that follows through criteria that the Secretary and inserting description of the criteria that the Secretary.

  16. Carried out:

    Section 351(i)(3) of the Public Health Service Act (42 U.S.C. 262(i)(3)) is amended by striking that is shown to meet the standards described in subsection (k)(4) and inserting licensed under subsection (k).

  17. Carried out:

    Section 351 of the Public Health Service Act (42 U.S.C. 262) is amended by adding at the end the following:(o) Certification of patent information in certain applications.— (1) In general.— An application submitted under this section for a biological product that includes a full report of a covered investigation shall also include— (A) a certification, in the opinion of the applicant …

§ 262(i)–(k)

Start of § 262 to (i)(2)(A) unchanged ·

(B) there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product.

(3) The term “interchangeable” or “interchangeability”, in reference to a biological product [struck: that][inserted: licensed] [struck: is][inserted: under] [struck: shown to meet the standards described in ]subsection (k)[struck: (4)], means that the biological product may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.

(4) The term “reference product” means the single biological product licensed under subsection (a) against which a biological product is evaluated in an application submitted under subsection (k).

(j) Application of Federal Food, Drug, and Cosmetic Act The Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.], including the requirements under sections 505(o), 505(p), and 505–1 of such Act [21 U.S.C. 355(o), (p), 355–1], applies to a biological product subject to regulation under this section, except that a product for which a license has been approved under subsection (a) shall not be required to have an approved application under section 505 of such Act.

(k) Licensure of biological products as biosimilar[struck: or interchangeable]

(1) In general Any person may submit an application for licensure of a biological product under this subsection.

(2) Content

(A) In general

(i) Required information An application submitted under this subsection shall include information demonstrating that—

[struck: (I)] [inserted: (i)] the biological product is biosimilar to a reference product based upon data derived from—

[struck: (aa)] [inserted: (I)] analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components;

[struck: (bb)] [inserted: (II)] an assessment of toxicity (which may rely on, or consist of, a study or studies described in [struck: item][inserted: subclause] ([struck: aa][inserted: I]) or ([struck: cc][inserted: III])); and

[struck: (cc)] [inserted: (III)] a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product;

[struck: (II)] [inserted: (ii)] the biological product and reference product utilize the same mechanism or mechanisms of action for the condition or conditions of use prescribed, recommended, or suggested in the proposed labeling, but only to the extent the mechanism or mechanisms of action are known for the reference product;

[struck: (III)] [inserted: (iii)] the condition or conditions of use prescribed, recommended, or suggested in the labeling proposed for the biological product have been previously approved for the reference product;

[struck: (IV)] [inserted: (iv)] the route of administration, the dosage form, and the strength of the biological product are the same as those of the reference product; and

[struck: (V)] [inserted: (v)] the facility in which the biological product is manufactured, processed, packed, or held meets standards designed to assure that the biological product continues to be safe, pure, and potent.

(ii) Determination by Secretary The Secretary may determine, in the Secretary’s discretion, that an element described in clause (i)(I) is unnecessary in an application submitted under this subsection.

(iii) Additional information An application submitted under this subsection—

(I) shall include publicly-available information regarding the Secretary’s previous determination that the reference product is safe, pure, and potent;

(II) may include any additional information in support of the application, including publicly-available information with respect to the reference product or another biological product; and

(III) may include information to show that the conditions of use prescribed, recommended, or suggested in the labeling proposed for the biological product have been previously approved for the reference product.

[struck: (B)] [struck: Interchangeability] [struck: An application (or a supplement to an application) submitted under this subsection may include information demonstrating that the biological product meets the standards described in paragraph (4).]

(3) Evaluation by Secretary Upon review of an application (or a supplement to an application) submitted under this subsection, the Secretary shall license the biological product under this subsection if—

(A) the Secretary determines that the information submitted in the application (or the supplement) is sufficient to show that the biological product—

(i) is biosimilar to the reference product; or

(ii) meets the standards described in paragraph (4), and therefore is interchangeable with the reference product; and

(B) the applicant (or other appropriate person) consents to the inspection of the facility that is the subject of the application, in accordance with subsection (c).

(4) [struck: Safety standards for determining interchangeability][inserted: Interchangeability.—] [struck: Upon review of an application submitted under this subsection or any supplement to such application, the Secretary shall determine the biological product to be interchangeable with the reference product if the Secretary determines that the information submitted in the application (or a supplement to such application) is sufficient to show that—]

(A) [inserted: In general.—] [inserted: A biological product licensed under this subsection shall be deemed to be interchangeable with the reference product, subject to subparagraph (B).]

[struck: the biological product—]

[struck: (i)] [struck: is biosimilar to the reference product; and]

[struck: (ii)] [struck: can be expected to produce the same clinical result as the reference product in any given patient; and]

(B) [inserted: Timing of deemed interchangeability.—]

(i) [inserted: Licensure on or after transition date.—] [inserted: A biological product licensed under this subsection on or after the transition date described in subparagraph (C) (in this clause referred to as the “applicable biological product”) shall be deemed to be interchangeable with the reference product upon such licensure, unless the applicable biological product relied on the same reference product as another biological product for which—]

(I) [inserted: licensure under this subsection was in effect on the day before the date of enactment of the Faster Clinical Trials Act; and]

(II) [inserted: a first interchangeable exclusivity period under paragraph (6) (as in effect on the day before the date of enactment of such Act) is in effect on the date of licensure of the applicable biological product,]

[inserted: in which case the applicable biological product shall be deemed interchangeable with the reference product under this paragraph on the date on which the exclusivity period described in subclause (II) ends.]

(ii) [inserted: Licensure prior to transition date.—] [inserted: A biological product licensed under this subsection prior to the transition date described in subparagraph (C) (referred to in this clause as the “applicable biological product”) shall be deemed to be interchangeable with the reference product on such transition date, unless the applicable biological product relied on the same reference product as another biological product for which—]

(I) [inserted: licensure under this subsection was in effect on the day before the date of enactment of the Faster Clinical Trials Act; and]

(II) [inserted: a first interchangeable exclusivity period under paragraph (6) (as in effect on the day before the date of enactment of such Act) is in effect on the transition date,]

[inserted: in which case the applicable biological product shall be deemed interchangeable with the reference product under this paragraph on the date on which the exclusivity period described in subclause (II) ends.]

(C) [inserted: Transition date.—] [inserted: The transition date described in this subparagraph is the date that is 60 days after the date of enactment of the Faster Clinical Trials Act.]

[struck: for a biological product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch.]

(5) General rules

(A) One reference product per application A biological product, in an application submitted under this subsection, may not be evaluated against more than 1 reference product.

(B) Review An application submitted under this subsection shall be reviewed by the division within the Food and Drug Administration that is responsible for the review and approval of the application under which the reference product is licensed.

(C) Risk evaluation and mitigation strategies The authority of the Secretary with respect to risk evaluation and mitigation strategies under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] shall apply to biological products licensed under this subsection in the same manner as such authority applies to biological products licensed under subsection (a).

(6) [struck: Exclusivity][inserted: Transition] [struck: for][inserted: with] [inserted: respect to preserving ]first interchangeable [inserted: exclusivity with respect to certain ]biological [struck: product][inserted: products.—] [inserted: With respect to a biological product licensed under this subsection before the date of enactment of the Faster Clinical Trials Act, for which there was an unexpired period of first interchangeable exclusivity under this subsection (as then in effect), such unexpired exclusivity period shall remain in effect for the duration of such period.]

[struck: The Secretary shall not make approval as an interchangeable biological product effective with respect to an application submitted under this subsection that relies on the same reference product for which a prior biological product has received a determination of interchangeability for any condition of use, until the earlier of—]

[struck: (A)] [struck: 1 year after the first commercial marketing of the first interchangeable biosimilar biological product to be approved as interchangeable for that reference product;]

[struck: (B)] [struck: 18 months after—]

[struck: (i)] [struck: a final court decision on all patents in suit in an action instituted under subsection (l)(6) against the applicant that submitted the application for the first approved interchangeable biosimilar biological product; or]

[struck: (ii)] [struck: the dismissal with or without prejudice of an action instituted under subsection (l)(6) against the applicant that submitted the application for the first approved interchangeable biosimilar biological product; or]

[struck: (C)]

[struck: (i)] [struck: 42 months after approval of the first interchangeable biosimilar biological product if the applicant that submitted such application has been sued under subsection (l)(6) and such litigation is still ongoing within such 42-month period; or]

[struck: (ii)] [struck: 18 months after approval of the first interchangeable biosimilar biological product if the applicant that submitted such application has not been sued under subsection (l)(6).]

[struck: For purposes of this paragraph, the term “final court decision” means a final decision of a court from which no appeal (other than a petition to the United States Supreme Court for a writ of certiorari) has been or can be taken, and the term “first interchangeable biosimilar biological product” means any interchangeable biosimilar biological product that is approved on the first day on which such a product is approved as interchangeable with the reference product.]

(7) Exclusivity for reference product

(A) Effective date of biosimilar application approval Approval of an application under this subsection may not be made effective by the Secretary until the date that is 12 years after the date on which the reference product was first licensed under subsection (a).

§ 262(k)(8)Guidance documents(C)–(E)

(k)(7)(B)–(8)(B) unchanged ·

(C) No requirement for application consideration The issuance (or non-issuance) of guidance under subparagraph (A) shall not preclude the review of, or action on, an application submitted under this subsection.

(D) Requirement for product class-specific guidance [inserted: If the Secretary issues product class-specific guidance under subparagraph (A), such guidance shall include a description of the criteria that the Secretary will use to determine whether a biological product is highly similar to a reference product in such product class.]

[struck: If the Secretary issues product class-specific guidance under subparagraph (A), such guidance shall include a description of—]

[struck: (i)] [struck: the criteria that the Secretary will use to determine whether a biological product is highly similar to a reference product in such product class; and]

[struck: (ii)] [struck: the criteria, if available, that the Secretary will use to determine whether a biological product meets the standards described in paragraph (4).]

(E) Certain product classes

(i) Guidance The Secretary may indicate in a guidance document that the science and experience, as of the date of such guidance, with respect to a product or product class (not including any recombinant protein) does not allow approval of an application for a license as provided under this subsection for such product or product class.

§ 262(n)–(o)

(k)(8)(E)(ii)–(n)(2) unchanged ·

(A) the date an application is approved under subsection (a); or

(B) the date of issuance of the interim final rule controlling the biological product.

(o) [inserted: Certification of patent information in certain applications.—]

(1) [inserted: In general.—] [inserted: An application submitted under this section for a biological product that includes a full report of a covered investigation shall also include—]

(A) [inserted: a certification, in the opinion of the applicant and to the best of their knowledge, with respect to each covered patent—]

(i) [inserted: that such patent information has not been filed;]

(ii) [inserted: that such patent has expired;]

(iii) [inserted: of the date on which such patent will expire; or]

(iv) [inserted: that such patent is invalid or will not be infringed by the manufacture, use, or sale of such product for which the application is submitted; and]

(B) [inserted: if information was filed under subsection (l) for a method of use patent which does not claim a use for which the applicant is seeking approval under this section, a statement that the method of use patent does not claim such a use.]

(2) [inserted: Definitions.—] [inserted: In this subsection:]

(A) [inserted: Covered investigation.—] [inserted: The term “covered investigation” means, with respect to a biological product for which an applicant submitted an application under this section, an investigation of such product that—]

(i) [inserted: was conducted to demonstrate whether such product is safe for use and is effective in use;]

(ii) [inserted: was not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigation was conducted; and]

(iii) [inserted: is relied upon by the applicant seeking approval of such application.]

(B) [inserted: Covered patent.—] [inserted: The term “covered patent” means a patent—]

(i) [inserted: which claims—]

(I) [inserted: the biological product for which a covered investigation was conducted; or]

(II) [inserted: a use for such product for which an applicant is seeking approval of an application under this section; and]

(ii) [inserted: for which information is required to be filed under subsection (l).]

42 U.S.C. § 263–1 Education on biological products

+5 −5Shown
More for 42 U.S.C. § 263–1
Read § 263–1Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 352A of the Public Health Service Act (42 U.S.C. 263–1) is amended by striking and interchangeable biosimilar biological products each place such term appears.

§ 263–1(a)

§ 263–1. Education on biological products

(a) Internet website

(1) In general The Secretary may maintain and operate an internet website to provide educational materials for health care providers, patients, and caregivers, regarding the meaning of the terms, and the standards for review and licensing of, biological products, including biosimilar biological products[struck: and interchangeable biosimilar biological products].

(2) Content Educational materials provided under paragraph (1) may include—

(A) explanations of key statutory and regulatory terms, including “biosimilar” and “interchangeable”, and clarification regarding the use of interchangeable biosimilar biological products;

(B) information related to development programs for biological products, including biosimilar biological products and [struck: interchangeable biosimilar biological products and ]relevant clinical considerations for prescribers, which may include, as appropriate and applicable, information related to the comparability of such biological products;

(C) an explanation of the process for reporting adverse events for biological products, including biosimilar biological products[struck: and interchangeable biosimilar biological products]; and

(D) an explanation of the relationship between biosimilar biological products [struck: and interchangeable biosimilar biological products ]licensed under section 262(k) of this title and reference products (as defined in section 262(i) of this title), including the standards for review and licensing of each such type of biological product.

(3) Format The educational materials provided under paragraph (1) may be—

(A) in formats such as webinars, continuing education modules, videos, fact sheets, infographics, stakeholder toolkits, or other formats as appropriate and applicable; and

§ 263–1(a)–(b)

(a)(3)(B)–(4)(B) unchanged ·

(5) Confidential and trade secret information This subsection does not authorize the disclosure of any trade secret, confidential commercial or financial information, or other matter described in section 552(b) of title 5.

(b) Continuing education The Secretary shall advance education and awareness among health care providers regarding biological products, including biosimilar biological products[struck: and interchangeable biosimilar biological products], as appropriate, including by developing or improving continuing education programs that advance the education of such providers on the prescribing of, and relevant clinical considerations with respect to, biological products, including biosimilar biological products[struck: and interchangeable biosimilar biological products].

Public Health Service Act § 499B Cures in Care Initiative establishment New section

+209 −0Shown
More for Public Health Service Act § 499B
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following:499B. Cures in Care Initiative establishment (a) Center for Clinical Trial Innovation.— The Secretary shall establish the Center for Clinical Trial Innovation (in this section referred to as the Center) within the Center for Drug Evaluation and Research of the Food and Drug Administration to carry out the Initiative established under subsection (b), to be headed by a director. (b) Establishment of Cures in Care Initiative.— (1) In general.— The Secretary, acting through the Assistant Secretary of Health shall continue a Cures in Care Initiative (in this section referred to as the Initiative) to expand, enhance, and promote routine point-of-care clinical trials, including through the establishment and support of broad-based clinical trial networks (in this section referred to as a lead network), for the purpose of accelerating the development of new treatments and cures by generating clinical evidence faster and through novel methods. (2) Coordination and implementation.— The Assistant Secretary of Health shall coordinate the activities of the Commissioner of Food and Drugs and the Director of the National Institutes of Health in implementing the Initiative. (3) Principal office.— The Secretary shall establish the Center for Clinical Trial Innovation (in this section referred to as the Center) within the Center for Drug Evaluation and Research of the Food and Drug Administration to serve as the principal implementing office supporting the Assistant Secretary of Health in carrying out the Initiative established under subsection (a), to be headed by a director. (c) Duties.— In carrying out the Initiative, the Director shall— (1) identify priority disease or mechanism areas for the purpose of implementing lead networks; (2) establish lead networks for each such a priority disease or mechanism area by building on existing clinical trial networks and infrastructures; (3) ensure each such network prioritizes the participation of less-resourced clinical trial settings; (4) ensure each such network focuses on not less than— (A) 1 high-burden chronic disease; and (B) 1 group of rare diseases that are related or similar to each other; (5) designate a central institutional review board to review any routine point-of-care clinical trial carried out by a lead network pursuant to this subsection; (6) coordinate actions carried out under the Initiative for purposes of addressing barriers to the conduct of routine point-of-care clinical trials carried out by a lead network pursuant to this subsection, with respect to— (A) shared or central institutional review board oversight; (B) patient consent, including electronic consent; (C) alignment of health information technology interoperability standards adopted by the Office of the National Coordinator for Health Information Technology, program data requirements administered by the Centers for Medicare & Medicaid Services and the real-world data standards maintained by the Commissioner of Food and Drugs, consistent with applicable privacy and confidentiality protections; (D) development of innovative clinical trial methods; (E) publication transparency and reproducibility; (F) digital tools and artificial intelligence to reduce the cost and burden of such clinical trials; (G) necessary infrastructure to implement a decentralized clinical trial network, in a hub-and-spoke model; and (H) governance of such clinical trials at multiple sites; (7) establish an Food and Drug Administration-endorsed clinical trial site certification program; and (8) in consultation with the Director of the National Center for Advancing Translational Sciences award grants and enter into contracts, cooperative agreements, and other transactions, including as authorized under sections 499A(g) and 499C. (d) Rapid implementation.— The Director shall— (1) establish not less than 3 lead networks under subsection (c) not later than 1 year after the date of enactment of this subsection; and (2) upon establishment of such lead networks, develop the plan described in subsection (e). (e) Implementation plan for expanding activities.— (1) In general.— Not later than 3 years after the date of enactment of this subsection, the Director shall implement a comprehensive implementation plan describing how the Initiative will broadly extend covered activities to the public and private development of medical products, including stretch goals with timeframes for— (A) achieving expanded patient access and site access to routine point-of-care clinical trials, including ensuring patient access at 60 percent of health care delivery sites and for 90 percent of eligible patients that participate in a clinical trial carried out by a lead network established under subsection (c); (B) reducing the cost of such a clinical trial, including approaching a 30 to 50 percent reduction in cost per patient and a 30 percent reduction in accrual time; (C) enhancing any impact of such a clinical trial, including ensuring that 90 percent of patients participating in such a clinical trial obtain a timely, independently reviewed, and publicly reported result; and (D) assessing if lead networks are improving trial execution, including site activation timelines, time to first patient enrolled, enrollment and retention performance, data quality, monitoring burden, technology and workflow readiness, and the long-term research readiness of participating sites. (2) Publication.— Not later than 3 years after the date of enactment of this paragraph, the Director shall make available to the public on the website of the Department of Health and Human Services the implementation plan implemented under paragraph (1). (3) Covered activity defined.— For purposes of paragraph (1), the term covered activity means— (A) identifying priority disease or mechanism areas under subsection (c) for the purpose of implementing broad-based point-of-care clinical trial networks; or (B) establishing a lead network under such subsection for each such priority disease or mechanism area. (f) Collaboration and consultation.— (1) Required collaboration and consultation.— In carrying out the Initiative, the Director shall collaborate and consult with— (A) the Administrator of the Centers for Medicare & Medicaid Services; (B) the Director of the Advanced Research Projects Agency–Health; (C) the Administrator of the Health Resources and Services Administration; (D) the Office of the National Coordinator for Health Information Technology; (E) the Director of the Center for Biologics Evaluation and Research; (F) the Office of the Assistant Secretary of Health; and (G) representatives from— (i) health care organizations in a lead network; (ii) network users, including researchers and clinical trial administrators; (iii) provider groups that do not directly collaborate with lead networks, including health systems, academic medical centers, and specialty medical societies; (iv) private and nonprofit organizations funding such organizations and groups; (v) patient advocacy organizations; (vi) contract research organizations; (vii) technology partners; and (viii) such other partner organizations as the Director determines appropriate. (2) Additional collaboration and consultation.— In addition to the collaboration and consultation required under paragraph (1), the Director may, as appropriate, collaborate and consult with— (A) the Secretary of Veterans Affairs; and (B) the Secretary of Defense, including the Director of the Defense Health Agency. (g) Training and technical assistance.— (1) In general.— In carrying out the Initiative, the Director, in consultation with the Director of the National Center for Advancing Translational Sciences, shall provide training and technical assistance to— (A) a lead network established under subsection (c); (B) a health care organization or other partner organization seeking to participate in a routine point-of-care clinical trial carried out by a lead network; (C) any entity that applies for a grant, cooperative agreement, contract, or other transaction under section 499C but does not receive such grant, cooperative agreement, contract, or other transaction; and (D) an emerging biotechnology company. (2) Contents.— In providing training and technical assistance under paragraph (1), the Director may address clinical development and regulatory subjects, including— (A) protocol development; (B) regulatory interactions with the Food and Drug Administration; (C) data infrastructure integration; (D) sponsor and site engagement in designing, conducting, and evaluating clinical trials; (E) sustainability planning; and (F) general public education on clinical trials and their potential risks and benefits. (3) Format.— The Director shall make these training and technical assistance materials available in an online resource center, including resources on— (A) staff training materials; (B) trial-network participation; (C) technology support; (D) data quality assessments; (E) Institutional Review Board templates and best practices; (F) study startup; and (G) capacity building. (4) Priority.— In carrying out this subsection, the Director shall give priority to less-resourced clinical trial settings. (5) Contracts and cooperative agreements for training.— The Director may enter into contracts or cooperative agreements with entities, such as the Reagan-Udall Foundation for the Food and Drug Administration established under section 770 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379dd), to— (A) establish training programs; and (B) hold meetings for health care organizations, clinical research organizations, technology partners, and patient-led organizations participating in a lead network established under subsection (c). (h) External engagement.— The Commissioner of Food and Drugs shall establish and expand the external engagement capacity of the Center through the performance commitments under section 736B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h–2). (i) FDA guidance.— Not later than 18 months after the date of enactment of this subsection, the Commissioner of Food and Drugs shall, in consultation with the Director, issue any draft or final guidance as may be necessary to carry out this section, including with respect to— (1) guidelines for carrying out routine point-of-care clinical trial networks, including governance, data monitoring, and application of an innovative clinical trial method, drawing on existing Food and Drug Administration guidance for platform studies; (2) any update to guidance on decentralized clinical trials, remote monitoring of such trials, and real-world data and real-world evidence; and (3) reliance on central institutional review boards and electronic consent in routine point-of-care clinical trials. (j) Reports.— (1) Annual reports.— Not later than 1 year after the date of enactment of this paragraph, and annually thereafter, the Director shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, and make available to the public on the website of the Department, a report on, with respect to the period covered by the report, the progress of the Initiative in advancing routine point-of-care clinical trials, with respect to each priority disease or mechanism area and lead network established under subsection (c), including— (A) progress addressing any barrier described in such subsection; (B) the availability and performance of any routine point-of-care clinical trial in the United States; (C) any trend in the United States with respect to such clinical trials; and (D) the participation rate of less-resourced clinical trial settings in each such lead network. (2) Evaluation reports.— (A) 3-year report.— Not later than 3 years after the date of enactment of this subparagraph, the Director shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing— (i) an evaluation of— (I) the outcome of any coordination, collaboration, and consultation required under this section, including the performance of each lead network established under subsection (c); (II) any expanded patient access and site access to routine point-of-care clinical trials that is attributable to the Initiative; (III) any improvement in the participation rate of less-resourced clinical trial settings that is attributable to the Initiative; (IV) any improvement in the participation rate of emerging biotechnology sponsors within the lead network; and (V) alignment of interagency action under this section; and (ii) any recommendation for additional legislative action to accelerate progress in carrying out routine point-of-care clinical trials and developing medical products. (B) 5-year report.— Not later than 5 years after the date of enactment of this subparagraph, the Director shall submit a report in such manner and containing such information as required under subparagraph (A). (k) Medical product defined.— In this section, the term medical product means— (1) a drug or device, as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321); or (2) a biological product, as defined in section 351 of this Act. (l) Authorization of appropriations.— In addition to any funds made available in the FDA Innovation Account under section 1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114–255) and any amount made available under section 499C, there is authorized to be appropriated to carry out this section $500,000,000 for each of fiscal years 2027 through 2031, to remain available until expended..

§ 499B(a)–(l)

§ 499B. [inserted: Cures in Care Initiative establishment]

(a) [inserted: Center for Clinical Trial Innovation.—] [inserted: The Secretary shall establish the Center for Clinical Trial Innovation (in this section referred to as the “Center”) within the Center for Drug Evaluation and Research of the Food and Drug Administration to carry out the Initiative established under subsection (b), to be headed by a director.]

(b) [inserted: Establishment of Cures in Care Initiative.—]

(1) [inserted: In general.—] [inserted: The Secretary, acting through the Assistant Secretary of Health shall continue a Cures in Care Initiative (in this section referred to as the “Initiative”) to expand, enhance, and promote routine point-of-care clinical trials, including through the establishment and support of broad-based clinical trial networks (in this section referred to as a “lead network”), for the purpose of accelerating the development of new treatments and cures by generating clinical evidence faster and through novel methods.]

(2) [inserted: Coordination and implementation.—] [inserted: The Assistant Secretary of Health shall coordinate the activities of the Commissioner of Food and Drugs and the Director of the National Institutes of Health in implementing the Initiative.]

(3) [inserted: Principal office.—] [inserted: The Secretary shall establish the Center for Clinical Trial Innovation (in this section referred to as the “Center”) within the Center for Drug Evaluation and Research of the Food and Drug Administration to serve as the principal implementing office supporting the Assistant Secretary of Health in carrying out the Initiative established under subsection (a), to be headed by a director.]

(c) [inserted: Duties.—] [inserted: In carrying out the Initiative, the Director shall—]

(1) [inserted: identify priority disease or mechanism areas for the purpose of implementing lead networks;]

(2) [inserted: establish lead networks for each such a priority disease or mechanism area by building on existing clinical trial networks and infrastructures;]

(3) [inserted: ensure each such network prioritizes the participation of less-resourced clinical trial settings;]

(4) [inserted: ensure each such network focuses on not less than—]

(A) [inserted: 1 high-burden chronic disease; and]

(B) [inserted: 1 group of rare diseases that are related or similar to each other;]

(5) [inserted: designate a central institutional review board to review any routine point-of-care clinical trial carried out by a lead network pursuant to this subsection;]

(6) [inserted: coordinate actions carried out under the Initiative for purposes of addressing barriers to the conduct of routine point-of-care clinical trials carried out by a lead network pursuant to this subsection, with respect to—]

(A) [inserted: shared or central institutional review board oversight;]

(B) [inserted: patient consent, including electronic consent;]

(C) [inserted: alignment of health information technology interoperability standards adopted by the Office of the National Coordinator for Health Information Technology, program data requirements administered by the Centers for Medicare & Medicaid Services and the real-world data standards maintained by the Commissioner of Food and Drugs, consistent with applicable privacy and confidentiality protections;]

(D) [inserted: development of innovative clinical trial methods;]

(E) [inserted: publication transparency and reproducibility;]

(F) [inserted: digital tools and artificial intelligence to reduce the cost and burden of such clinical trials;]

(G) [inserted: necessary infrastructure to implement a decentralized clinical trial network, in a hub-and-spoke model; and]

(H) [inserted: governance of such clinical trials at multiple sites;]

(7) [inserted: establish an Food and Drug Administration-endorsed clinical trial site certification program; and]

(8) [inserted: in consultation with the Director of the National Center for Advancing Translational Sciences award grants and enter into contracts, cooperative agreements, and other transactions, including as authorized under sections 499A(g) and 499C.]

(d) [inserted: Rapid implementation.—] [inserted: The Director shall—]

(1) [inserted: establish not less than 3 lead networks under subsection (c) not later than 1 year after the date of enactment of this subsection; and]

(2) [inserted: upon establishment of such lead networks, develop the plan described in subsection (e).]

(e) [inserted: Implementation plan for expanding activities.—]

(1) [inserted: In general.—] [inserted: Not later than 3 years after the date of enactment of this subsection, the Director shall implement a comprehensive implementation plan describing how the Initiative will broadly extend covered activities to the public and private development of medical products, including stretch goals with timeframes for—]

(A) [inserted: achieving expanded patient access and site access to routine point-of-care clinical trials, including ensuring patient access at 60 percent of health care delivery sites and for 90 percent of eligible patients that participate in a clinical trial carried out by a lead network established under subsection (c);]

(B) [inserted: reducing the cost of such a clinical trial, including approaching a 30 to 50 percent reduction in cost per patient and a 30 percent reduction in accrual time;]

(C) [inserted: enhancing any impact of such a clinical trial, including ensuring that 90 percent of patients participating in such a clinical trial obtain a timely, independently reviewed, and publicly reported result; and]

(D) [inserted: assessing if lead networks are improving trial execution, including site activation timelines, time to first patient enrolled, enrollment and retention performance, data quality, monitoring burden, technology and workflow readiness, and the long-term research readiness of participating sites.]

(2) [inserted: Publication.—] [inserted: Not later than 3 years after the date of enactment of this paragraph, the Director shall make available to the public on the website of the Department of Health and Human Services the implementation plan implemented under paragraph (1).]

(3) [inserted: Covered activity defined.—] [inserted: For purposes of paragraph (1), the term “covered activity” means—]

(A) [inserted: identifying priority disease or mechanism areas under subsection (c) for the purpose of implementing broad-based point-of-care clinical trial networks; or]

(B) [inserted: establishing a lead network under such subsection for each such priority disease or mechanism area.]

(f) [inserted: Collaboration and consultation.—]

(1) [inserted: Required collaboration and consultation.—] [inserted: In carrying out the Initiative, the Director shall collaborate and consult with—]

(A) [inserted: the Administrator of the Centers for Medicare & Medicaid Services;]

(B) [inserted: the Director of the Advanced Research Projects Agency–Health;]

(C) [inserted: the Administrator of the Health Resources and Services Administration;]

(D) [inserted: the Office of the National Coordinator for Health Information Technology;]

(E) [inserted: the Director of the Center for Biologics Evaluation and Research;]

(F) [inserted: the Office of the Assistant Secretary of Health; and]

(G) [inserted: representatives from—]

(i) [inserted: health care organizations in a lead network;]

(ii) [inserted: network users, including researchers and clinical trial administrators;]

(iii) [inserted: provider groups that do not directly collaborate with lead networks, including health systems, academic medical centers, and specialty medical societies;]

(iv) [inserted: private and nonprofit organizations funding such organizations and groups;]

(v) [inserted: patient advocacy organizations;]

(vi) [inserted: contract research organizations;]

(vii) [inserted: technology partners; and]

(viii) [inserted: such other partner organizations as the Director determines appropriate.]

(2) [inserted: Additional collaboration and consultation.—] [inserted: In addition to the collaboration and consultation required under paragraph (1), the Director may, as appropriate, collaborate and consult with—]

(A) [inserted: the Secretary of Veterans Affairs; and]

(B) [inserted: the Secretary of Defense, including the Director of the Defense Health Agency.]

(g) [inserted: Training and technical assistance.—]

(1) [inserted: In general.—] [inserted: In carrying out the Initiative, the Director, in consultation with the Director of the National Center for Advancing Translational Sciences, shall provide training and technical assistance to—]

(A) [inserted: a lead network established under subsection (c);]

(B) [inserted: a health care organization or other partner organization seeking to participate in a routine point-of-care clinical trial carried out by a lead network;]

(C) [inserted: any entity that applies for a grant, cooperative agreement, contract, or other transaction under section 499C but does not receive such grant, cooperative agreement, contract, or other transaction; and]

(D) [inserted: an emerging biotechnology company.]

(2) [inserted: Contents.—] [inserted: In providing training and technical assistance under paragraph (1), the Director may address clinical development and regulatory subjects, including—]

(A) [inserted: protocol development;]

(B) [inserted: regulatory interactions with the Food and Drug Administration;]

(C) [inserted: data infrastructure integration;]

(D) [inserted: sponsor and site engagement in designing, conducting, and evaluating clinical trials;]

(E) [inserted: sustainability planning; and]

(F) [inserted: general public education on clinical trials and their potential risks and benefits.]

(3) [inserted: Format.—] [inserted: The Director shall make these training and technical assistance materials available in an online resource center, including resources on—]

(A) [inserted: staff training materials;]

(B) [inserted: trial-network participation;]

(C) [inserted: technology support;]

(D) [inserted: data quality assessments;]

(E) [inserted: Institutional Review Board templates and best practices;]

(F) [inserted: study startup; and]

(G) [inserted: capacity building.]

(4) [inserted: Priority.—] [inserted: In carrying out this subsection, the Director shall give priority to less-resourced clinical trial settings.]

(5) [inserted: Contracts and cooperative agreements for training.—] [inserted: The Director may enter into contracts or cooperative agreements with entities, such as the Reagan-Udall Foundation for the Food and Drug Administration established under section 770 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379dd), to—]

(A) [inserted: establish training programs; and]

(B) [inserted: hold meetings for health care organizations, clinical research organizations, technology partners, and patient-led organizations participating in a lead network established under subsection (c).]

(h) [inserted: External engagement.—] [inserted: The Commissioner of Food and Drugs shall establish and expand the external engagement capacity of the Center through the performance commitments under section 736B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h–2).]

(i) [inserted: FDA guidance.—] [inserted: Not later than 18 months after the date of enactment of this subsection, the Commissioner of Food and Drugs shall, in consultation with the Director, issue any draft or final guidance as may be necessary to carry out this section, including with respect to—]

(1) [inserted: guidelines for carrying out routine point-of-care clinical trial networks, including governance, data monitoring, and application of an innovative clinical trial method, drawing on existing Food and Drug Administration guidance for platform studies;]

(2) [inserted: any update to guidance on decentralized clinical trials, remote monitoring of such trials, and real-world data and real-world evidence; and]

(3) [inserted: reliance on central institutional review boards and electronic consent in routine point-of-care clinical trials.]

(j) [inserted: Reports.—]

(1) [inserted: Annual reports.—] [inserted: Not later than 1 year after the date of enactment of this paragraph, and annually thereafter, the Director shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, and make available to the public on the website of the Department, a report on, with respect to the period covered by the report, the progress of the Initiative in advancing routine point-of-care clinical trials, with respect to each priority disease or mechanism area and lead network established under subsection (c), including—]

(A) [inserted: progress addressing any barrier described in such subsection;]

(B) [inserted: the availability and performance of any routine point-of-care clinical trial in the United States;]

(C) [inserted: any trend in the United States with respect to such clinical trials; and]

(D) [inserted: the participation rate of less-resourced clinical trial settings in each such lead network.]

(2) [inserted: Evaluation reports.—]

(A) [inserted: 3-year report.—] [inserted: Not later than 3 years after the date of enactment of this subparagraph, the Director shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing—]

(i) [inserted: an evaluation of—]

(I) [inserted: the outcome of any coordination, collaboration, and consultation required under this section, including the performance of each lead network established under subsection (c);]

(II) [inserted: any expanded patient access and site access to routine point-of-care clinical trials that is attributable to the Initiative;]

(III) [inserted: any improvement in the participation rate of less-resourced clinical trial settings that is attributable to the Initiative;]

(IV) [inserted: any improvement in the participation rate of emerging biotechnology sponsors within the lead network; and]

(V) [inserted: alignment of interagency action under this section; and]

(ii) [inserted: any recommendation for additional legislative action to accelerate progress in carrying out routine point-of-care clinical trials and developing medical products.]

(B) [inserted: 5-year report.—] [inserted: Not later than 5 years after the date of enactment of this subparagraph, the Director shall submit a report in such manner and containing such information as required under subparagraph (A).]

(k) [inserted: Medical product defined.—] [inserted: In this section, the term “medical product” means—]

(1) [inserted: a drug or device, as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321); or]

(2) [inserted: a biological product, as defined in section 351 of this Act.]

(l) [inserted: Authorization of appropriations.—] [inserted: In addition to any funds made available in the FDA Innovation Account under section 1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114–255) and any amount made available under section 499C, there is authorized to be appropriated to carry out this section $500,000,000 for each of fiscal years 2027 through 2031, to remain available until expended.]

Public Health Service Act § 499C Cures in Care Initiative lead network grant program New section

+88 −0Shown
More for Public Health Service Act § 499C
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following:499C. Cures in Care Initiative lead network grant program (a) In general.— Not later than 5 years after the date of enactment of this subsection, the Commissioner of Food and Drugs, in consultation with the Director of the Center for Clinical Trial Innovation, and the Director of the National Institutes of Health, acting through the Center for Advancing Translational Sciences and the Advanced Research Projects Agency–Health, (in this section referred to as the Commissioner and Director) shall make grants to, or enter into cooperative agreements, contracts, or other transactions with, not fewer than 3 lead networks established under section 499B(c) to— (1) achieve not later than 3 years after the date on which an appropriation is first made under subsection (e), measurable improvements in the clinical evidence base for each priority disease or mechanism area for which such network was established; and (2) enable broader implementation of routine point-of-care clinical trials beyond such lead network. (b) Use of funds.— The Commissioner and Director may require a lead network that receives a grant, or enters into a cooperative agreement, contract, or other transaction, under this section to use any funding received through such grant, cooperative agreement, contract, or transaction to— (1) implement the data sharing standards described under section 105 of the Faster Clinical Trials Act; (2) implement site data infrastructure and clinical research technology; (3) leverage existing clinical trial networks, Federal digital health and artificial intelligence initiatives, and virtual participation options, consistent with good clinical practice; (4) provide a plan for reliable collection and sharing of data on covariates, treatments, outcomes, and adverse events with respect to the applicable disease or mechanism area; (5) support, as appropriate— (A) phase 2 and 3 clinical trials; (B) label expansion studies; (C) comparative effectiveness studies; and (D) post-market commitments and phase 4 commitments; (6) include sites and patients from less-resourced clinical trial settings; (7) include patients from populations not primarily served by academic health centers; (8) include emerging biotechnology companies; (9) establish grants specifically for less-resourced sites, including federally qualified health centers, to enable participation; (10) collaborate or partner with multiple commercial developers of medical products (as defined in section 499B) that are active in the applicable disease or mechanism area; and (11) include a plan for sustainability with respect to a routine point-of-care clinical trial carried out by such platform, including a description of— (A) any partial startup funding from a non-Federal source; (B) an additional study on the common trial platform to be carried out after the date on which the period described in subsection (c) ends; and (C) an understanding of how lead networks will maintain infrastructure and research beyond initial Federal support, including long-term site readiness, staffing and workforce support, technology maintenance, continued community-site participation, sponsor adoption and utilization, and the operational resources necessary to support multiple studies over time. (c) Duration.— (1) In general.— Subject to paragraph (2), a grant, cooperation agreement, contract, or other transaction under this section shall be for a period of not more than 5 years. (2) Extension for material contribution.— The Commissioner and Director may extend the 5-year period described in paragraph (1) by not more than 3 years if the Commissioner and Director determine that such extension will materially contribute to fulfillment of the implementation plan required under section 499B. (d) Evaluation.— (1) In general.— The Cures in Care Initiative Collaborative established under section 499D shall evaluate any activity carried out using any funds received through a grant, cooperative agreement, contract, or transaction under this section, including— (A) a partnership between a lead network and a sponsor or health care organization that are additional sites of care; (B) compared to traditional baselines, the cost of— (i) recruiting, enrolling, and treating each patient enrolled in a routine point-of-care clinical trial; and (ii) completing each such trial; (C) any research impact such an activity has on— (i) such clinical trials; (ii) any site in which such a clinical trial is performed; and (iii) any effect on the evidence base; (D) inclusion of less-resourced clinical trial settings; and (E) any opportunity to increase scaling and sustainability with respect to such a clinical trial carried out by a lead network that receives such funds, including— (i) a maintenance plan for clinical trial sites to continue participating after the initial grant period ends; and (ii) continued education for sites and training opportunities for staff. (2) Publication.— Not later than 3 years after the date of enactment of this paragraph, and annually thereafter, the Collaborative shall make available to the public on the website of the Department of Health and Human Services the evaluation carried out under paragraph (1). (e) Budget clarification; agency contributions.— (1) Authorization of appropriations.— There is authorized to be appropriated to carry out this section such sums as necessary for each of fiscal years 2027 through 2031, to remain available until expended. (2) Common Fund.— The Commissioner and Director may reserve to carry out this section any amounts made available under paragraph (1) for the Common Fund established under section 402A(c)(1). (3) Budget clarification.— Any budget request of the President shall specify an amount for carrying out this section. (4) Agency contributions.— In addition to any funds made available under section 402A(a)(3), the Secretary may transfer funds from other departmental agencies and programs to carry out the Initiative established under section 499B, including the grant program established under this section, provided such funds do not supplant funding under such section and such transfer will further the authorized programs of the contributing agency or program..

§ 499C(a)–(e)

§ 499C. [inserted: Cures in Care Initiative lead network grant program]

(a) [inserted: In general.—] [inserted: Not later than 5 years after the date of enactment of this subsection, the Commissioner of Food and Drugs, in consultation with the Director of the Center for Clinical Trial Innovation, and the Director of the National Institutes of Health, acting through the Center for Advancing Translational Sciences and the Advanced Research Projects Agency–Health, (in this section referred to as the “Commissioner and Director”) shall make grants to, or enter into cooperative agreements, contracts, or other transactions with, not fewer than 3 lead networks established under section 499B(c) to—]

(1) [inserted: achieve not later than 3 years after the date on which an appropriation is first made under subsection (e), measurable improvements in the clinical evidence base for each priority disease or mechanism area for which such network was established; and]

(2) [inserted: enable broader implementation of routine point-of-care clinical trials beyond such lead network.]

(b) [inserted: Use of funds.—] [inserted: The Commissioner and Director may require a lead network that receives a grant, or enters into a cooperative agreement, contract, or other transaction, under this section to use any funding received through such grant, cooperative agreement, contract, or transaction to—]

(1) [inserted: implement the data sharing standards described under section 105 of the Faster Clinical Trials Act;]

(2) [inserted: implement site data infrastructure and clinical research technology;]

(3) [inserted: leverage existing clinical trial networks, Federal digital health and artificial intelligence initiatives, and virtual participation options, consistent with good clinical practice;]

(4) [inserted: provide a plan for reliable collection and sharing of data on covariates, treatments, outcomes, and adverse events with respect to the applicable disease or mechanism area;]

(5) [inserted: support, as appropriate—]

(A) [inserted: phase 2 and 3 clinical trials;]

(B) [inserted: label expansion studies;]

(C) [inserted: comparative effectiveness studies; and]

(D) [inserted: post-market commitments and phase 4 commitments;]

(6) [inserted: include sites and patients from less-resourced clinical trial settings;]

(7) [inserted: include patients from populations not primarily served by academic health centers;]

(8) [inserted: include emerging biotechnology companies;]

(9) [inserted: establish grants specifically for less-resourced sites, including federally qualified health centers, to enable participation;]

(10) [inserted: collaborate or partner with multiple commercial developers of medical products (as defined in section 499B) that are active in the applicable disease or mechanism area; and]

(11) [inserted: include a plan for sustainability with respect to a routine point-of-care clinical trial carried out by such platform, including a description of—]

(A) [inserted: any partial startup funding from a non-Federal source;]

(B) [inserted: an additional study on the common trial platform to be carried out after the date on which the period described in subsection (c) ends; and]

(C) [inserted: an understanding of how lead networks will maintain infrastructure and research beyond initial Federal support, including long-term site readiness, staffing and workforce support, technology maintenance, continued community-site participation, sponsor adoption and utilization, and the operational resources necessary to support multiple studies over time.]

(c) [inserted: Duration.—]

(1) [inserted: In general.—] [inserted: Subject to paragraph (2), a grant, cooperation agreement, contract, or other transaction under this section shall be for a period of not more than 5 years.]

(2) [inserted: Extension for material contribution.—] [inserted: The Commissioner and Director may extend the 5-year period described in paragraph (1) by not more than 3 years if the Commissioner and Director determine that such extension will materially contribute to fulfillment of the implementation plan required under section 499B.]

(d) [inserted: Evaluation.—]

(1) [inserted: In general.—] [inserted: The Cures in Care Initiative Collaborative established under section 499D shall evaluate any activity carried out using any funds received through a grant, cooperative agreement, contract, or transaction under this section, including—]

(A) [inserted: a partnership between a lead network and a sponsor or health care organization that are additional sites of care;]

(B) [inserted: compared to traditional baselines, the cost of—]

(i) [inserted: recruiting, enrolling, and treating each patient enrolled in a routine point-of-care clinical trial; and]

(ii) [inserted: completing each such trial;]

(C) [inserted: any research impact such an activity has on—]

(i) [inserted: such clinical trials;]

(ii) [inserted: any site in which such a clinical trial is performed; and]

(iii) [inserted: any effect on the evidence base;]

(D) [inserted: inclusion of less-resourced clinical trial settings; and]

(E) [inserted: any opportunity to increase scaling and sustainability with respect to such a clinical trial carried out by a lead network that receives such funds, including—]

(i) [inserted: a maintenance plan for clinical trial sites to continue participating after the initial grant period ends; and]

(ii) [inserted: continued education for sites and training opportunities for staff.]

(2) [inserted: Publication.—] [inserted: Not later than 3 years after the date of enactment of this paragraph, and annually thereafter, the Collaborative shall make available to the public on the website of the Department of Health and Human Services the evaluation carried out under paragraph (1).]

(e) [inserted: Budget clarification; agency contributions.—]

(1) [inserted: Authorization of appropriations.—] [inserted: There is authorized to be appropriated to carry out this section such sums as necessary for each of fiscal years 2027 through 2031, to remain available until expended.]

(2) [inserted: Common Fund.—] [inserted: The Commissioner and Director may reserve to carry out this section any amounts made available under paragraph (1) for the Common Fund established under section 402A(c)(1).]

(3) [inserted: Budget clarification.—] [inserted: Any budget request of the President shall specify an amount for carrying out this section.]

(4) [inserted: Agency contributions.—] [inserted: In addition to any funds made available under section 402A(a)(3), the Secretary may transfer funds from other departmental agencies and programs to carry out the Initiative established under section 499B, including the grant program established under this section, provided such funds do not supplant funding under such section and such transfer will further the authorized programs of the contributing agency or program.]

Public Health Service Act § 499D Cures in Care Initiative Collaborative New section

+37 −0Shown
More for Public Health Service Act § 499D
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following:499D. Cures in Care Initiative Collaborative (a) In general.— The Secretary, acting through the Director of NIH and the Director of the Center for Clinical Trial Innovation, shall establish, through entering into a contract, cooperative agreement, memorandum of understanding, or other mechanism, a public-private partnership, to be known as the Cures in Care Initiative Collaborative (in this section referred to as the Collaborative), to— (1) promote routine point-of-care clinical trials, including the development of novel trial methodologies; (2) promote the elimination of barriers to trial initiation and completion; and (3) support lead networks under the Cures in Care Initiative established under section 499B. (b) Required activities.— The Collaborative shall— (1) establish user groups, workshops, and other forums for sponsors, contract research organizations, health care organizations, technology providers, patient organizations, and Federal agencies to identify and address implementation barriers to routine point-of-care clinical trials; (2) provide technical assistance, including on protocol development, regulatory interactions, and data infrastructure, to sponsors of routine point-of-care clinical trials and lead networks that receive a grant, or enter into a cooperative agreement, contract, or other transaction, under section 499C; (3) support sandbox testing of innovations in trial design, data infrastructure, consent, and governance prior to broader adoption of such innovations; (4) evaluate incentives to support and sustain site participation in clinical trial networks; (5) maintain public reporting on progress, barriers, and outcomes of routine point-of-care clinical trial innovation; (6) coordinate with— (A) existing public-private partnerships on routine point-of-care clinical trial innovation; (B) existing research infrastructures within the National Institutes of Health and the Advanced Research Projects Agency–Health; and (C) the Center for Medicare and Medicaid Innovation established under section 1115A of the Social Security Act (42 U.S.C. 1315a), except that the Collaborative may not direct, or be directed by, such Center; (7) carry out the evaluation required under section 499C(d); (8) support practical technology and operational enablement of lead networks, including development and testing of integrated technology packages that can provide participating sites with interoperable tools, standardized workflows, training, implementation support, monitoring and data quality capabilities, and centralized technical assistance for less resourced sites; and (9) assess opportunities to centralize services, including patient recruitment, to reduce the burden of participation for clinical trial sites. (c) Federal Advisory Committee Act applicability.— Chapter 10 of title 5, United States Code, shall not apply to the Collaborative..

§ 499D(a)–(c)

§ 499D. [inserted: Cures in Care Initiative Collaborative]

(a) [inserted: In general.—] [inserted: The Secretary, acting through the Director of NIH and the Director of the Center for Clinical Trial Innovation, shall establish, through entering into a contract, cooperative agreement, memorandum of understanding, or other mechanism, a public-private partnership, to be known as the Cures in Care Initiative Collaborative (in this section referred to as the “Collaborative”), to—]

(1) [inserted: promote routine point-of-care clinical trials, including the development of novel trial methodologies;]

(2) [inserted: promote the elimination of barriers to trial initiation and completion; and]

(3) [inserted: support lead networks under the Cures in Care Initiative established under section 499B.]

(b) [inserted: Required activities.—] [inserted: The Collaborative shall—]

(1) [inserted: establish user groups, workshops, and other forums for sponsors, contract research organizations, health care organizations, technology providers, patient organizations, and Federal agencies to identify and address implementation barriers to routine point-of-care clinical trials;]

(2) [inserted: provide technical assistance, including on protocol development, regulatory interactions, and data infrastructure, to sponsors of routine point-of-care clinical trials and lead networks that receive a grant, or enter into a cooperative agreement, contract, or other transaction, under section 499C;]

(3) [inserted: support sandbox testing of innovations in trial design, data infrastructure, consent, and governance prior to broader adoption of such innovations;]

(4) [inserted: evaluate incentives to support and sustain site participation in clinical trial networks;]

(5) [inserted: maintain public reporting on progress, barriers, and outcomes of routine point-of-care clinical trial innovation;]

(6) [inserted: coordinate with—]

(A) [inserted: existing public-private partnerships on routine point-of-care clinical trial innovation;]

(B) [inserted: existing research infrastructures within the National Institutes of Health and the Advanced Research Projects Agency–Health; and]

(C) [inserted: the Center for Medicare and Medicaid Innovation established under section 1115A of the Social Security Act (42 U.S.C. 1315a), except that the Collaborative may not direct, or be directed by, such Center;]

(7) [inserted: carry out the evaluation required under section 499C(d);]

(8) [inserted: support practical technology and operational enablement of lead networks, including development and testing of integrated technology packages that can provide participating sites with interoperable tools, standardized workflows, training, implementation support, monitoring and data quality capabilities, and centralized technical assistance for less resourced sites; and]

(9) [inserted: assess opportunities to centralize services, including patient recruitment, to reduce the burden of participation for clinical trial sites.]

(c) [inserted: Federal Advisory Committee Act applicability.—] [inserted: Chapter 10 of title 5, United States Code, shall not apply to the Collaborative.]

Public Health Service Act § 499E Definitions for Cures in Care Initiative and related activities New section

+42 −0Shown
More for Public Health Service Act § 499E
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following:499E. Definitions for Cures in Care Initiative and related activities In this part: (1) Clinical investigation.— The term clinical investigation has the meaning given such term in section 50.3 of title 21, Code of Federal Regulations (or any successor regulation). (2) Innovative clinical trial method.— The term innovative clinical trial method includes adaptive, decentralized, Bayesian, platform, and external-control trial designs, as such terms are described in guidance issued by the Food and Drug Administration, including pursuant to section 3021 of the 21st Century Cures Act (21 U.S.C. 355 note) and section 3606 of the Consolidated Appropriations Act, 2023 (21 U.S.C. 360a–1 note). (3) Lead disease or mechanism area.— The term lead disease or mechanism area means a disease, condition, or disease-mechanism area that presents substantial opportunity for scaled, reusable platforms for routine point-of-care clinical trials. (4) Lead network.— The term lead network means a network of participating health care organizations for a lead disease or mechanism area. (5) Less-resourced clinical trial setting.— The term less-resourced clinical trial setting means a health care organization or provider that— (A) is located in, or primarily serves, a medically underserved community (as defined in section 799B(6) of this Act); or (B) is— (i) a Federally qualified health center (as defined in section 1861 of the Social Security Act (42 U.S.C. 1395x)); (ii) a rural health clinic (as defined in such section); (iii) a critical access hospital (as defined in such section); (iv) a health center that, during the period in which such center is in a lead network established under section 499B(c) of this Act, receives a grant under section 330; (v) a hospital that, during such period, receives a disproportionate share payment under section 1886(d)(5)(F) of the Social Security Act (42 U.S.C. 1395ww(d)(5)(F)); (vi) a facility owned or operated by the Indian Health Service; (vii) a facility operated by an Indian Tribe, Tribal organization, or an urban Indian organization (as such terms are defined in section 4 of the Indian Health Care Improvement Act (25 U.S.C. 1603)); or (viii) a health care provider that, during such period, receives a grant under title XXVI of the Public Health Service Act (42 U.S.C. 300ff et seq.) (commonly known as the Ryan White HIV/AIDS program). (6) Routine point-of-care clinical trial.— The term routine point-of-care clinical trial means a clinical investigation of a medical product (as defined in section 499B of this Act) that— (A) is integrated into clinical practice, including routine in-person or virtual visits; (B) includes health providers as investigators; (C) may be conducted in a primary care setting, an outpatient care setting, the home of a patient participating in such investigation, or a similar location; and (D) may follow a streamlined protocol and procedures focused on essential data collection generating or incorporating real-world data from an electronic or other health record..

§ 499E(1)–(6)

§ 499E. [inserted: Definitions for Cures in Care Initiative and related activities]

[inserted: In this part:]

(1) [inserted: Clinical investigation.—] [inserted: The term “clinical investigation” has the meaning given such term in section 50.3 of title 21, Code of Federal Regulations (or any successor regulation).]

(2) [inserted: Innovative clinical trial method.—] [inserted: The term “innovative clinical trial method” includes adaptive, decentralized, Bayesian, platform, and external-control trial designs, as such terms are described in guidance issued by the Food and Drug Administration, including pursuant to section 3021 of the 21st Century Cures Act (21 U.S.C. 355 note) and section 3606 of the Consolidated Appropriations Act, 2023 (21 U.S.C. 360a–1 note).]

(3) [inserted: Lead disease or mechanism area.—] [inserted: The term “lead disease or mechanism area” means a disease, condition, or disease-mechanism area that presents substantial opportunity for scaled, reusable platforms for routine point-of-care clinical trials.]

(4) [inserted: Lead network.—] [inserted: The term “lead network” means a network of participating health care organizations for a lead disease or mechanism area.]

(5) [inserted: Less-resourced clinical trial setting.—] [inserted: The term “less-resourced clinical trial setting” means a health care organization or provider that—]

(A) [inserted: is located in, or primarily serves, a medically underserved community (as defined in section 799B(6) of this Act); or]

(B) [inserted: is—]

(i) [inserted: a Federally qualified health center (as defined in section 1861 of the Social Security Act (42 U.S.C. 1395x));]

(ii) [inserted: a rural health clinic (as defined in such section);]

(iii) [inserted: a critical access hospital (as defined in such section);]

(iv) [inserted: a health center that, during the period in which such center is in a lead network established under section 499B(c) of this Act, receives a grant under section 330;]

(v) [inserted: a hospital that, during such period, receives a disproportionate share payment under section 1886(d)(5)(F) of the Social Security Act (42 U.S.C. 1395ww(d)(5)(F));]

(vi) [inserted: a facility owned or operated by the Indian Health Service;]

(vii) [inserted: a facility operated by an Indian Tribe, Tribal organization, or an urban Indian organization (as such terms are defined in section 4 of the Indian Health Care Improvement Act (25 U.S.C. 1603)); or]

(viii) [inserted: a health care provider that, during such period, receives a grant under title XXVI of the Public Health Service Act (42 U.S.C. 300ff et seq.) (commonly known as the Ryan White HIV/AIDS program).]

(6) [inserted: Routine point-of-care clinical trial.—] [inserted: The term “routine point-of-care clinical trial” means a clinical investigation of a medical product (as defined in section 499B of this Act) that—]

(A) [inserted: is integrated into clinical practice, including routine in-person or virtual visits;]

(B) [inserted: includes health providers as investigators;]

(C) [inserted: may be conducted in a primary care setting, an outpatient care setting, the home of a patient participating in such investigation, or a similar location; and]

(D) [inserted: may follow a streamlined protocol and procedures focused on essential data collection generating or incorporating real-world data from an electronic or other health record.]

21 U.S.C. § 379j–51 Definitions

Couldn't place the change
More for 21 U.S.C. § 379j–51
Read § 379j–51Only this section
Step through the changes